Interaction of growth hormone-releasing factor (GRF) and 14 GRF analogs with vasoactive intestinal peptide (VIP) receptors of rat pancreas. Discovery of (N-Ac-Tyr1,D-Phe2)-GRF(1-29)-NH2 as a VIP antagonist.

Waelbroeck M, Robberecht P, Coy DH, Camus JC, De Neef P, Christophe J

Endocrinology1 Jun 1985Cited by 107 (Europe PMC)

PMID2859987DOI10.1210/endo-116-6-2643PepBankPUB-02859987

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

01LabNot a test of Sermorelin aloneIn vitro (cell-free)Activity measurement
In rat pancreatic plasma membranes, GRF and its analogs interfered with VIP receptors by inhibiting [125I]iodo-VIP binding.
In plain wordsIn lab tests on rat pancreas membranes, GRF and its analogs blocked the binding of VIP to its receptors.
Peptide
Sermorelin
Outcome
DecreaseInhibition of [125I]iodo-VIP binding
Study
ratn: not reported in source
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Source sentences
Summary
These peptides interfered with VIP receptors as they inhibited [125I]iodo-VIP binding
1 context sentence(design, population, supporting numbers)
Summary · context
Adenylate cyclase stimulation by GH-releasing factor (GRF) and 14 GRF analogs (modified in the N-terminal part) was compared to the capacity of the same peptides to inhibit [125I]iodo-vasoactive intestinal peptide (VIP) binding in rat pancreatic plasma membranes.
In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.
Report a problemFND-0285998701
02LabNot a test of Sermorelin aloneIn vitro (cell-free)Activity measurement
In rat pancreatic plasma membranes, the analog (N-Ac-Tyr1,D-Phe2)-GRF(1-29)-NH2 selectively inhibited both VIP- and GRF-stimulated adenylate cyclase activities.
In plain wordsIn lab tests on rat pancreas membranes, one GRF analog blocked the enzyme activity switched on by both VIP and GRF.
Peptide
Sermorelin
Outcome
DecreaseInhibition of GRF-stimulated adenylate cyclase by (N-Ac-Tyr1,D-Phe2)-GRF(1-29)-NH2
Study
ratn: not reported in source
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Source sentences
Summary
selectively inhibited both VIP- and GRF-stimulated adenylate cyclase activities
1 context sentence(design, population, supporting numbers)
Summary · context
Adenylate cyclase stimulation by GH-releasing factor (GRF) and 14 GRF analogs (modified in the N-terminal part) was compared to the capacity of the same peptides to inhibit [125I]iodo-vasoactive intestinal peptide (VIP) binding in rat pancreatic plasma membranes.
In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.
Report a problemFND-0285998702
03LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cell-free)Activity measurement
In rat pancreatic plasma membranes, GRF and GRF analogs inhibited [125I]iodo-VIP binding to VIP receptors.
In plain wordsIn lab tests on rat pancreas membranes, GRF and related peptides blocked VIP from binding to its receptors.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreaseInhibition of [125I]iodo-VIP binding by GRF and GRF analogs
Study
ratn: not reported in source
Rat pancreatic plasma membranes
Outcome group
Receptor activity and mechanism · Pharmacology
Source sentences
Summary
These peptides interfered with VIP receptors as they inhibited [125I]iodo-VIP binding
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-0285998703
04LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cell-free)Mechanism
In rat pancreatic plasma membranes, the GRF analog (N-Ac-Tyr1,D-Phe2)-GRF(1-29)-NH2 selectively inhibited both VIP- and GRF-stimulated adenylate cyclase activities.
In plain wordsIn lab tests on rat pancreas membranes, one GRF analog blocked the enzyme activity that VIP and GRF switch on.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreaseInhibition of VIP-stimulated adenylate cyclase by (N-Ac-Tyr1,D-Phe2)-GRF(1-29)-NH2
Study
ratn: not reported in source
Rat pancreatic plasma membranes
Outcome group
Receptor activity and mechanism · Pharmacology
Source sentences
Summary
as one of these peptides [(N-Ac-Tyr1,D-Phe2)-GRF(1-29)-NH2] selectively inhibited both VIP- and GRF-stimulated adenylate cyclase activities.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-0285998704

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 3 to 38Current
28 Oct 2026, 02:04 UTC
The same notice was added 36 times, first on 9 Oct 2026, 19:08 UTC. The status did not change between them.
Study results updated
Version 2
9 Oct 2026, 12:41 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:13 UTC
First added · source update from Europe PMC